Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hiroki Nagai
Observed names:
H Nagai,
H. Nagai,
HIROKI NAGAI
Institutions:
Kobe Medical Center,
Kobe City Medical Center General Hospital
Observed institutions:
Kyoto University,
Valley Hospital,
Kobe Medical Center,
Kyoto University Hospital,
Kobe City Medical Center General Hospital
ORCID:
0000-0003-1673-2647
Observed ORCID:
0000-0003-1673-2647
OpenAlex ID:
A5102821926
Works
90
Awards
1
Cancer prevention from the perspective of global cancer burden patterns
2017
·
Hiroki Nagai
, Young Hak Kim
·
Journal of Thoracic Disease
·
686
PDF
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
2012
·
Yosuke Togashi
, Katsuhiro Masago
, et al.
·
Cancer Chemotherapy and Pharmacology
·
295
PDF
Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis
2023
·
Takuji Okusaka
, Masafumi Nakamura
, et al.
·
International Journal of Clinical Oncology
·
210
PDF
Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients
2017
·
Takashi Nomizo
, Hiroaki Ozasa
, et al.
·
Scientific Reports
·
117
PDF
Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer
2016
·
Yoshihisa Kobayashi
, Koichi Azuma
, et al.
·
Molecular Cancer Therapeutics
·
82
Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab
2017
·
Motoo Nomura
, Atsushi Otsuka
, et al.
·
Cancer Chemotherapy and Pharmacology
·
64
Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update
2018
·
Hiroki Nagai
, Manabu Muto
·
International Journal of Clinical Oncology
·
61
Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model
2018
·
Takahiro Tsuji
, Hiroaki Ozasa
, et al.
·
Molecular Cancer Research
·
52
PDF
Prognostic Significance of Preexisting Interstitial Lung Disease in Japanese Patients With Small-Cell Lung Cancer
2011
·
Yosuke Togashi
, Katsuhiro Masago
, et al.
·
Clinical Lung Cancer
·
47
PDF
Pneumatosis Cystoides Intestinalis After Gefitinib Therapy for Pulmonary Adenocarcinoma
2011
·
Masahiro Iwasaku
, Hiroshige Yoshioka
, et al.
·
Journal of Thoracic Oncology
·
44
PDF
Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer
2013
·
Yuka Kuriyama
, Young Hak Kim
, et al.
·
Case Reports in Oncology
·
43
Nivolumab in non-small-cell lung cancer with EGFR mutation
2017
·
H. Yoshida
, Y.H. Kim
, et al.
·
Annals of Oncology
·
41
High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib
2013
·
Young Hak Kim
, Hiroaki Ozasa
, et al.
·
Journal of Thoracic Oncology
·
39
Effect of vascular endothelial growth factor polymorphisms on survival in advanced‐stage non‐small‐cell lung cancer
2009
·
Katsuhiro Masago
, Shiro Fujita
, et al.
·
Cancer Science
·
39
PDF
Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer
2011
·
Yosuke Togashi
, Katsuhiro Masago
, et al.
·
Lung Cancer
·
34
Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
2021
·
Tatsuki Ikoma
, Mototsugu Shimokawa
, et al.
·
BMC Cancer
·
33
PDF
Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature
2012
·
Yosuke Togashi
, Katsuhiro Masago
, et al.
·
Lung Cancer
·
30
PDF
Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in�vitro and in�vivo
2012
·
Hiroki Nagai
, Hiroyasu Yasuda
, et al.
·
International Journal of Oncology
·
26
PDF
Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab
2022
·
Tatsuki Ikoma
, Mototsugu Shimokawa
, et al.
·
Cancer Immunology Immunotherapy
·
24
Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received Gefitinib
2010
·
Katsuhiro Masago
, Shiro Fujita
, et al.
·
Oncology
·
22
Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab
2019
·
Tomoko Yamamoto Funazo
, Takashi Nomizo
, et al.
·
Scientific Reports
·
21
PDF
Increase in circulating endothelial progenitor cells predicts response in patients with advanced non‐small‐cell lung cancer
2012
·
Yuichi Sakamori
, Katsuhiro Masago
, et al.
·
Cancer Science
·
19
Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer
2016
·
HIRONORI YOSHIDA
, YOUNG HAK KIM
, et al.
·
Molecular and Clinical Oncology
·
17
PDF
Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer
2017
·
Takahiro Tsuji
, Yuichi Sakamori
, et al.
·
Oncotarget
·
15
Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901
2013
·
Young Hak Kim
, Masataka Hirabayashi
, et al.
·
Cancer Chemotherapy and Pharmacology
·
15
Show more works
View as search
Works count:
90
Citation count:
2,328
H-index:
21
I10-index:
38
Year
Topic
Type